Charles Schwab’s Lunai Bioworks LNAI Stock Holding History

Charles Schwab’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,527	Closed	-$197K	–	3561
2025 Q1	$197K	Hold	4,527	–	–	﹤0.01%	3261
2024 Q4	$303K	Buy	4,527 +2,040	+82%	+$135K	﹤0.01%	3269
2024 Q3	$96.2K	Hold	2,487	–	–	﹤0.01%	3378
2024 Q2	$348K	Buy	+2,487	New	+$339K	﹤0.01%	3327
2023 Q2	–	Sell	-543	Closed	-$39.7K	–	3668
2023 Q1	$39.7K	Sell	543 -94	-15%	-$8.27K	﹤0.01%	3386
2022 Q4	$52.5K	Hold	637	–	–	﹤0.01%	3348
2022 Q3	$93K	Hold	637	–	–	﹤0.01%	3230
2022 Q2	$99K	Buy	+637	New	+$291K	﹤0.01%	3289
2021 Q2	–	Sell	-367	Closed	-$104K	–	3518
2021 Q1	$104K	Sell	367 -89	-20%	-$26.2K	﹤0.01%	3378
2020 Q4	$108K	Hold	456	–	–	﹤0.01%	3317
2020 Q3	$131K	Hold	456	–	–	﹤0.01%	3231
2020 Q2	$154K	Hold	456	–	–	﹤0.01%	3202
2020 Q1	$110K	Hold	456	–	–	﹤0.01%	3101
2019 Q4	$184K	Buy	456 +265	+139%	+$116K	﹤0.01%	3050
2019 Q3	$84K	Hold	191	–	–	﹤0.01%	3104
2019 Q2	$69K	Buy	+191	New	+$93.1K	﹤0.01%	3136

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Charles Schwab's LNAI Position: Q2 2025 in Review

Charles Schwab sold out of Lunai Bioworks (LNAI) in Q2 2025, closing a stake of 4,527 shares — an estimated $197K sold.

Charles Schwab first reported a position in LNAI in Q2 2019 and held it in 16 quarters. The position peaked at $348K in Q2 2024. 42 funds tracked by Wall St. Rank hold LNAI as of Q2 2025.

Charles Schwab reported no remaining Lunai Bioworks position as of Q2 2025 after selling out during the quarter.
Charles Schwab sold 4,527 Lunai Bioworks shares in Q2 2025, an estimated $197K.
Charles Schwab first reported a position in Lunai Bioworks in Q2 2019 and held it in 16 quarters.
Charles Schwab's Lunai Bioworks position peaked at $348K in Q2 2024.
42 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.